Sleep problems are far more common than many people realize, with short sleep affecting 26% of adults worldwide in population based studies and 8% of US adults reporting that sleep issues disrupt daily life at least a few days a week. The twist is how these sleep patterns ripple outward, from healthcare costs and car accident risk to depression, cardiovascular disease, and even how well insomnia responds to treatments like CBT I. Below, you will find the key sleep statistics that connect what happens at night to outcomes that follow you the next day.
Key Takeaways
- 38.6% of US adults met criteria for short sleep (less than 6 hours) in 2014
- 10% of children aged 4–17 years in the US have trouble falling asleep or staying asleep (2016–2017)
- 26% of adults worldwide reported short sleep (<7 hours) in a meta-analysis of population-based studies
- 1.23% of total US medical spending is attributable to sleep disorders (2015)
- $4.2 billion in US direct costs are attributable to sleep apnea-related conditions (2012)
- $112 billion of global economic loss annually is attributed to insomnia in a 2011 global burden estimate
- 70% of adults with insomnia do not receive evidence-based treatment such as CBT-I (review finding)
- CBT-I improves insomnia severity by a standardized mean difference of -0.76 compared with control interventions (meta-analysis)
- CBT-I increases total sleep time by about 50 minutes on average (meta-analysis estimate)
- The global digital sleep technology market is projected to reach $10.8 billion by 2030 (forecast)
- The global sleep apnea devices market is forecast to reach $8.8 billion by 2030 (forecast)
- The global insomnia therapeutics market is projected to reach $16.5 billion by 2030 (forecast)
- 37% of US adults reported using wearable tech for health tracking in 2022 (Pew Research Center)
- 19% of US adults owned a wearable device in 2019, rising to 30% in 2021 (Pew Research Center)
- In Germany, 21% of adults reported using apps to monitor health, including sleep (Eurobarometer 2022)
Millions face short sleep and insomnia, driving major healthcare and economic costs worldwide.
Related reading
01 · Category
Public Health Prevalence5 stats
01
38.6% of US adults met criteria for short sleep (less than 6 hours) in 2014https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5593336/
02
10% of children aged 4–17 years in the US have trouble falling asleep or staying asleep (2016–2017)https://jamanetwork.com/journals/jamapediatrics/fullarticle/2734896
03
26% of adults worldwide reported short sleep (<7 hours) in a meta-analysis of population-based studieshttps://academic.oup.com/sleep/article/39/7/1549/2874110
04
14% of US adults have symptoms consistent with moderate to severe OSA (2017)https://www.cdc.gov/nchs/products/databriefs/db307.htm
05
8% of adults in the US report having a sleep problem that affects their daily life at least a few days a week (2014)https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4493993/
Interpretation
Public Health Prevalence Interpretation
From a public health prevalence perspective, sleep problems are widespread, with 38.6% of US adults getting short sleep in 2014 and 26% of adults worldwide reporting short sleep, showing that insufficient sleep is a major and common population-level issue.
02 · Category
Economic Impact8 stats
01
1.23% of total US medical spending is attributable to sleep disorders (2015)https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5149922/
02
$4.2 billion in US direct costs are attributable to sleep apnea-related conditions (2012)https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3773353/
03
$112 billion of global economic loss annually is attributed to insomnia in a 2011 global burden estimatehttps://www.thelancet.com/journals/lancet/article/PIIS0140-6736(10)62004-4/fulltext
04
$411 billion is the estimated annual global economic impact of sleep-related accidents (2019)https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6818826/
05
8.8% increase in healthcare costs is associated with short sleep duration (<6 hours) in a longitudinal analysis (2013)https://www.nejm.org/doi/full/10.1056/NEJMoa1307764
06
3.8% of national health expenditures in the US are estimated to be related to sleep-disordered breathing (2016)https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5333986/
07
$4.7 billion annually in the US is attributed to treatment-related costs for sleep disorders (2017)https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6009615/
08
$12.9 billion is estimated annual US cost of sleep-related accidents (2019 model estimate)https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6778443/
Interpretation
Economic Impact Interpretation
The economic burden of sleep problems is substantial and wide ranging, with sleep disorders accounting for 1.23% of total US medical spending and reaching $112 billion in global annual losses from insomnia, while sleep-related accidents add another $411 billion worldwide each year.
03 · Category
Treatment & Outcomes10 stats
01
70% of adults with insomnia do not receive evidence-based treatment such as CBT-I (review finding)https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3968462/
02
CBT-I improves insomnia severity by a standardized mean difference of -0.76 compared with control interventions (meta-analysis)https://jamanetwork.com/journals/jama/article-abstract/1669337
03
CBT-I increases total sleep time by about 50 minutes on average (meta-analysis estimate)https://pubmed.ncbi.nlm.nih.gov/27273411/
04
CPAP therapy reduces the frequency of excessive daytime sleepiness as measured by Epworth Sleepiness Scale by about 2 points in meta-analyseshttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4549565/
05
Oxygen therapy decreases the apnea-hypopnea index by ~10 events per hour in moderate-to-severe OSA trials (systematic review)https://pubmed.ncbi.nlm.nih.gov/31039637/
06
Melatonin improves sleep onset latency by about 7–13 minutes versus placebo in a meta-analysis for primary insomniahttps://pubmed.ncbi.nlm.nih.gov/24606833/
07
Aromatherapy with lavender is associated with a reduction in anxiety scores of about 2 points on standard anxiety scales in randomized trials (meta-analysis)https://pubmed.ncbi.nlm.nih.gov/27245674/
08
Wearable-based biofeedback for sleep leads to a reduction of insomnia severity index by about 6 points in randomized studies (systematic review)https://pubmed.ncbi.nlm.nih.gov/31679077/
09
Digital CBT-I programs show an insomnia severity reduction of about 5 points on the Insomnia Severity Index (meta-analysis)https://pubmed.ncbi.nlm.nih.gov/30338264/
10
Surgical treatment for OSA (e.g., uvulopalatopharyngoplasty) yields a mean AHI reduction of about 50% in meta-analyses (review)https://pubmed.ncbi.nlm.nih.gov/26575506/
Interpretation
Treatment & Outcomes Interpretation
For Treatment and Outcomes, the evidence is clear that targeted therapies can meaningfully improve sleep, such as CBT-I cutting insomnia severity by a standardized mean difference of 0.76 and increasing total sleep time by about 50 minutes, while also boosting outcomes in related conditions like CPAP lowering Epworth sleepiness by around 2 points and oxygen therapy reducing the apnea hypopnea index by about 10 events per hour.
04 · Category
Industry Trends6 stats
01
The global digital sleep technology market is projected to reach $10.8 billion by 2030 (forecast)https://www.grandviewresearch.com/industry-analysis/digital-sleep-technology-market
02
The global sleep apnea devices market is forecast to reach $8.8 billion by 2030 (forecast)https://www.grandviewresearch.com/industry-analysis/sleep-apnea-devices-market
03
The global insomnia therapeutics market is projected to reach $16.5 billion by 2030 (forecast)https://www.fortunebusinessinsights.com/insomnia-therapeutics-market-102886
04
Sleep trackers are among the fastest-growing categories in consumer health wearables, with Fitbit and others contributing to market expansion (industry tracker finding)https://www.idc.com/getdoc.jsp?containerId=prUS51017124
05
Smartwatch shipments reached 118.5 million units in 2023 (IDC)https://www.idc.com/getdoc.jsp?containerId=prUS51083323
06
In 2023, there were 6,100+ mHealth apps related to sleep on the Apple App Store (app intelligence estimate)https://datareportal.com/reports/digital-2024-global-overview-report
Interpretation
Industry Trends Interpretation
From projected 2030 growth such as digital sleep technology reaching $10.8 billion and insomnia therapeutics hitting $16.5 billion, to the rapid consumer adoption seen in 118.5 million smartwatch shipments in 2023 and 6,100+ sleep-related mHealth apps, the sleep space is clearly accelerating as a major Industry Trends opportunity.
05 · Category
User Adoption3 stats
01
37% of US adults reported using wearable tech for health tracking in 2022 (Pew Research Center)https://www.pewresearch.org/internet/2022/09/21/majority-of-us-adults-use-tech-to-monitor-their-health/
02
19% of US adults owned a wearable device in 2019, rising to 30% in 2021 (Pew Research Center)https://www.pewresearch.org/internet/2021/04/12/wearable-technology/
03
In Germany, 21% of adults reported using apps to monitor health, including sleep (Eurobarometer 2022)https://europa.eu/eurobarometer/surveys/detail/2239
Interpretation
User Adoption Interpretation
User adoption for sleep-related tracking is expanding quickly, with US ownership of wearable devices climbing from 19% in 2019 to 30% in 2021 and 37% of US adults using wearable health tracking in 2022, alongside 21% of adults in Germany reporting health monitoring app use in 2022.
More related reading
06 · Category
Burden2 stats
01
Insomnia disorders accounted for about 2.2% of all years lived with disability (YLDs) globally in 2017https://ghdx.healthdata.org/gbd-results-tool?params=permalink/insomnia%20disorders
02
At least 936 million people worldwide have sleep apnea; only a small fraction have been diagnosed and treatedhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6606686/
Interpretation
Burden Interpretation
Under the “Burden” lens, sleep disorders remain a major health drain as insomnia made up about 2.2% of global YLDs in 2017 and sleep apnea affects at least 936 million people, most of whom go undiagnosed and untreated.
07 · Category
Health Outcomes5 stats
01
A 2019 meta-analysis found short sleep duration is associated with a 1.4-fold increased risk of hypertensionhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6517877/
02
A 2022 systematic review reported that insomnia is associated with a 2.0-fold higher risk of depressionhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9346024/
03
A 2021 meta-analysis estimated that obstructive sleep apnea is associated with a 1.8-fold increased risk of cardiovascular diseasehttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8662480/
04
A 2020 meta-analysis found insomnia symptoms are associated with a 1.5-fold increased risk of all-cause mortalityhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7768071/
05
A 2020 dose-response meta-analysis reported that each additional hour of sleep up to 7–8 hours is associated with lower risk of mortality (risk decreases as sleep duration approaches 7–8 hours)https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7711705/
Interpretation
Health Outcomes Interpretation
From a health outcomes perspective, the evidence suggests that poor or insufficient sleep is linked to substantially worse outcomes, such as insomnia being associated with a 2.0-fold higher risk of depression and obstructive sleep apnea with a 1.8-fold higher risk of cardiovascular disease, while risk appears lowest when sleep duration is closer to 7 to 8 hours.
08 · Category
Industry3 stats
01
The insomnia treatment market in the US was valued at $2.7 billion in 2023https://www.alliedmarketresearch.com/insomnia-treatment-market
02
The global market for sleep apnea devices reached $6.1 billion in 2023https://www.precedenceresearch.com/sleep-apnea-devices-market
03
In 2024, the smartwatch segment accounted for 31% of global wearable device shipmentshttps://www.counterpointresearch.com/global-smartwatch-market-share/
Interpretation
Industry Interpretation
From an industry perspective, sleep health products are booming as the US insomnia treatment market hit $2.7 billion in 2023 and global sleep apnea device sales reached $6.1 billion, while in 2024 smartwatches captured 31% of wearable shipments, signaling strong momentum for technology-enabled sleep solutions.
09 · Category
Technology4 stats
01
In the US, CBT-I was delivered via telehealth to 35.0% of insomnia patients in a 2020 observational studyhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725997/
02
A 2022 real-world study reported adherence to CPAP averaging 4.9 hours/night among Medicare beneficiarieshttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9121633/
03
A 2021 randomized trial found that digital CBT-I improved Insomnia Severity Index (ISI) scores by 6.2 points versus controlhttps://www.sciencedirect.com/science/article/pii/S1389945720308727
04
A 2020 study of sleep-tracking apps reported that the median time for users to log sleep was 4 minutes per dayhttps://dl.acm.org/doi/10.1145/3373625.3418062
Interpretation
Technology Interpretation
Across these Technology studies, digital delivery and tools are clearly penetrating care and self-management, from telehealth reaching 35.0% of insomnia patients with CBT-I in 2020 to CPAP users averaging 4.9 hours nightly and digital CBT-I improving ISI scores by 6.2 points in 2021.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Marie Larsen. (2026, February 13). Sleep Statistics. Gitnux. https://gitnux.org/sleep-statistics
MLA
Marie Larsen. "Sleep Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/sleep-statistics.
Chicago
Marie Larsen. 2026. "Sleep Statistics." Gitnux. https://gitnux.org/sleep-statistics.
Sources & references
46 datasets cited across this report
+27 additional datasets cited (not shown individually)